Cheng V S, Suit H D, Wang C C, Raker J, Weymuller E, Kaufman S
Cancer. 1978 Oct;42(4):1912-5. doi: 10.1002/1097-0142(197810)42:4<1912::aid-cncr2820420432>3.0.co;2-5.
Twenty-one patients with squamous cell carcinoma of oral cavity and/or cervical lymph node and four patients with soft tissue sarcomas were given intralesional (2-4 mg/m2) and intralymph node (2-4 mg/m2) C. parvum injections followed by 5 intravenous (2-4 mg/m2) C. parvum treatments and conventional therapies. Seven patients with Stage III ovarian carcinomas were given intraperitoneal (2-4 mg/m2) C. parvum injections followed by conventional therapies. The local and systemic effects of the C. parvum treatments were described and the anti-tumor effects were evaluated in this series of patients.
21例口腔鳞状细胞癌和/或颈部淋巴结癌患者以及4例软组织肉瘤患者接受了瘤内（2 - 4mg/m²）和淋巴结内（2 - 4mg/m²）注射微小隐孢子虫，随后进行5次静脉注射（2 - 4mg/m²）微小隐孢子虫治疗及常规治疗。7例III期卵巢癌患者接受了腹腔内（2 - 4mg/m²）注射微小隐孢子虫，随后进行常规治疗。描述了微小隐孢子虫治疗的局部和全身效应，并对这一系列患者的抗肿瘤效果进行了评估。
